DENTSPLY SIRONA shares fell 6.2% after the company cut its full-year adjusted EPS outlook to $1.20–$1.30 from $1.40–$1.50, citing business pressures that cost actions have not fully offset. The weaker outlook came alongside a 7% constant-currency revenue decline and lower adjusted EBITDA margin.
- Q3 revenue was $836 million, down 7.6% as reported and 7% in constant currency; excluding Byte, planned dealer inventory reductions and other one-time events, revenue declined 3.8% in constant currency.
- Full-year net sales are now expected to be approximately $3.5 billion, versus the prior range of $3.5 billion–$3.6 billion. The EPS outlook excludes a $0.17 one-time gain from tariff refunds.
- Adjusted gross margin rose 190 basis points, but adjusted gross profit fell approximately $20 million. A $39 million accounting-estimate benefit boosted Q3 gross profit and pre-tax income; the company said it does not expect a similar benefit in future periods.
- Adjusted EBITDA margin declined 110 basis points, and adjusted EPS was $0.29, down $0.13 year over year. Operating cash flow fell to $32 million from $79 million, primarily due to unfavorable working capital.
- Wellspect posted record double-digit revenue growth, while CTS sales fell 11% as reported, reflecting broader equipment headwinds and lower CAD/CAM volumes in the Americas.
Community Discussion